Observational Study to Evaluate the Effectiveness and Safety of Levemir®, NovoMix® 30 and NovoRapid® in Insulin naïve Subjects With Type 2 Diabetes

Novo Nordisk

Status: Completed

Conditions: Diabetes; Diabetes Mellitus, Type 2

Treatments: Drug: biphasic insulin aspart 30; Drug: insulin detemir; Drug: insulin aspart

Study type: Observational

Funder types: Industry

Identifiers

NCT00771680

INS-3655

Details and patient eligibility

About

This study is conducted in Europe and Asia. The aim of this observational study is to evaluate the effectiveness and the incidence of serious adverse reactions while using Levemir®, NovoMix® and/or NovoRapid® in subjects with type 2 diabetes that have not used insulin previously under normal clinical practice conditions.

Enrollment: 10,408 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Any insulin näive type 2 diabetic patient that able to use the drug as judged by the investigator

Exclusion criteria

• In accordance with approved label

Trial design

10,408 participants in 1 patient group

A

Treatment:

Drug: insulin aspart

Drug: biphasic insulin aspart 30

Drug: insulin detemir